These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16013961)

  • 41. The feasibility of oligogenic combined segregation and linkage analysis in CEPH pedigrees.
    Daw EW; Yu R
    BMC Proc; 2007; 1 Suppl 1(Suppl 1):S108. PubMed ID: 18466448
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach.
    Ho GT; Soranzo N; Nimmo ER; Tenesa A; Goldstein DB; Satsangi J
    Hum Mol Genet; 2006 Mar; 15(5):797-805. PubMed ID: 16434479
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment.
    Khokhar JY; Ferguson CS; Zhu AZ; Tyndale RF
    Annu Rev Pharmacol Toxicol; 2010; 50():39-61. PubMed ID: 20055697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.
    Wark L; Novak D; Sabbaghian N; Amrein L; Jangamreddy JR; Cheang M; Pouchet C; Aloyz R; Foulkes WD; Mai S; Tischkowitz M
    Genes Chromosomes Cancer; 2013 May; 52(5):480-94. PubMed ID: 23341105
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Candidate gene approach for pharmacogenetic studies.
    Ring HZ; Kroetz DL
    Pharmacogenomics; 2002 Jan; 3(1):47-56. PubMed ID: 11966402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity.
    Huang RS; Duan S; Bleibel WK; Kistner EO; Zhang W; Clark TA; Chen TX; Schweitzer AC; Blume JE; Cox NJ; Dolan ME
    Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9758-63. PubMed ID: 17537913
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines.
    Choy E; Yelensky R; Bonakdar S; Plenge RM; Saxena R; De Jager PL; Shaw SY; Wolfish CS; Slavik JM; Cotsapas C; Rivas M; Dermitzakis ET; Cahir-McFarland E; Kieff E; Hafler D; Daly MJ; Altshuler D
    PLoS Genet; 2008 Nov; 4(11):e1000287. PubMed ID: 19043577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model.
    Jack J; Rotroff D; Motsinger-Reif A
    Curr Mol Med; 2014; 14(7):833-40. PubMed ID: 25109794
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro screening for population variability in chemical toxicity.
    O'Shea SH; Schwarz J; Kosyk O; Ross PK; Ha MJ; Wright FA; Rusyn I
    Toxicol Sci; 2011 Feb; 119(2):398-407. PubMed ID: 20952501
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics.
    Hariani GD; Lam ET; Havener T; Kwok PY; McLeod HL; Wagner MJ; Motsinger-Reif AA
    BMC Res Notes; 2014 Jun; 7():360. PubMed ID: 24924344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity.
    Fridley BL; Jenkins G; Schaid DJ; Wang L
    Stat Med; 2009 Sep; 28(21):2709-22. PubMed ID: 19572260
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenomic Discovery Delineating the Genetic Basis of Drug Response.
    Zhang W; Zheng Y; Hou L
    Curr Genet Med Rep; 2013 Sep; 1(3):143-149. PubMed ID: 24015375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extensive epigenetic and transcriptomic variability between genetically identical human B-lymphoblastoid cells with implications in pharmacogenomics research.
    Ozgyin L; Horvath A; Hevessy Z; Balint BL
    Sci Rep; 2019 Mar; 9(1):4889. PubMed ID: 30894562
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extending the lymphoblastoid cell line model for drug combination pharmacogenomics.
    Green AJ; Anchang B; Akhtari FS; Reif DM; Motsinger-Reif A
    Pharmacogenomics; 2021 Jun; 22(9):543-551. PubMed ID: 34044623
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines.
    Brown CC; Havener TM; Medina MW; Jack JR; Krauss RM; McLeod HL; Motsinger-Reif AA
    Pharmacogenomics; 2014 Feb; 15(2):137-46. PubMed ID: 24444404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacogenomic and clinical data link non-pharmacokinetic metabolic dysregulation to drug side effect pathogenesis.
    Zielinski DC; Filipp FV; Bordbar A; Jensen K; Smith JW; Herrgard MJ; Mo ML; Palsson BO
    Nat Commun; 2015 Jun; 6():7101. PubMed ID: 26055627
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity.
    Hartford CM; Dolan ME
    Pharmacogenomics; 2007 Sep; 8(9):1159-68. PubMed ID: 17924831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful use of long-term frozen lymphocytes for the establishment of lymphoblastoid cell lines.
    Tremblay S; Khandjian EW
    Clin Biochem; 1998 Oct; 31(7):555-6. PubMed ID: 9812176
    [No Abstract]   [Full Text] [Related]  

  • 59. Utility of lymphoblastoid cell lines.
    Sie L; Loong S; Tan EK
    J Neurosci Res; 2009 Jul; 87(9):1953-9. PubMed ID: 19224581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Star allele search: a pharmacogenetic annotation database and user-friendly search tool of publicly available 1000 Genomes Project biospecimens.
    Gharani N; Calendo G; Kusic D; Madzo J; Scheinfeldt L
    BMC Genomics; 2024 Jan; 25(1):116. PubMed ID: 38279110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.